Glioma Stem Cells as Immunotherapeutic Targets: Advancements and Challenges.

Authors

Keenan J Piper, Swedish Medical Group, 550 17th Avenue Suite 540, Seattle, WA 98122, USAFollow
Lisa DePledge, Ben & Catherine Ivy Center for Advanced Brain Tumor Treatment, Swedish Neuroscience Institute, Seattle, WA, United States.
Michael Karsy
Charles Cobbs, The Ben and Catherine Ivy Center for Advanced Brain Tumor Treatment, Swedish Neuroscience InstituteFollow

Document Type

Article

Publication Date

1-1-2021

Publication Title

Front Oncol

Keywords

washington; seattle; swedish neuro

Abstract

Glioblastoma is the most common and lethal primary brain malignancy. Despite major investments in research into glioblastoma biology and drug development, treatment remains limited and survival has not substantially improved beyond 1-2 years. Cancer stem cells (CSC) or glioma stem cells (GSC) refer to a population of tumor originating cells capable of self-renewal and differentiation. While controversial and challenging to study, evidence suggests that GCSs may result in glioblastoma tumor recurrence and resistance to treatment. Multiple treatment strategies have been suggested at targeting GCSs, including immunotherapy, posttranscriptional regulation, modulation of the tumor microenvironment, and epigenetic modulation. In this review, we discuss recent advances in glioblastoma treatment specifically focused on targeting of GCSs as well as their potential integration into current clinical pathways and trials.

Clinical Institute

Neurosciences (Brain & Spine)

Department

Neurosciences

Recommended Citation

Piper, Keenan J; DePledge, Lisa; Karsy, Michael; and Cobbs, Charles, "Glioma Stem Cells as Immunotherapeutic Targets: Advancements and Challenges." (2021). Articles, Abstracts, and Reports. 4571.
https://digitalcommons.providence.org/publications/4571